How GLP-1 Weight-Loss Drugs Work—and Why the New Wegovy Pill is a Breakthrough

The era of the weekly weight-loss injection is facing its first major disruption. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has officially approved Novo Nordisk's Wegovy as a once-daily pill, making Britain the first country in Europe to greenlight the oral formulation of the blockbuster drug.[1][3]

The approval marks a critical milestone in obesity care, offering a highly effective alternative for patients who are needle-averse or seeking more flexibility in their treatment regimens. Until now, the most potent pharmacological treatments for weight loss—including Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide)—have only been available as subcutaneous injections.[3][8]

With roughly 15 million people in the UK living with obesity, demand for these therapies has vastly outstripped global supply. The introduction of a daily tablet is expected to broaden access, though it will initially launch via private prescription while awaiting a formal cost-effectiveness review by the National Institute for Health and Care Excellence (NICE) for broader National Health Service (NHS) use.[3][7]

To understand why a pill form of Wegovy is a scientific breakthrough, it is necessary to understand how these medications work in the body. Wegovy belongs to a class of drugs known as GLP-1 receptor agonists, which have revolutionized metabolic medicine over the past decade.[4]

GLP-1, or glucagon-like peptide-1, is an incretin hormone naturally produced by the L-cells in the small intestine immediately after eating. Its primary physiological job is to signal the pancreas to release insulin, which helps clear glucose from the bloodstream and maintain stable blood sugar levels.[6][8]

However, GLP-1 also acts powerfully on the brain and the digestive system. It binds to specific receptors in the hypothalamus and brainstem, directly suppressing hunger signals and increasing feelings of satiety. Simultaneously, it slows gastric emptying—the rate at which food leaves the stomach—meaning patients feel physically fuller for much longer after a meal.[6][8]

While natural GLP-1 is broken down by the body's enzymes in a matter of minutes, synthetic semaglutide is engineered to resist degradation, remaining active in the system for days. This prolonged, artificial activation of the body's satiety signals is what drives the dramatic reduction in caloric intake and subsequent weight loss.[5][6]

Eli Lilly's rival medication, Mounjaro (tirzepatide), takes this mechanism a step further by utilizing a "dual-action" approach. In addition to GLP-1, Mounjaro also mimics a second incretin hormone called GIP (glucose-dependent insulinotropic polypeptide).[3][6]

While GIP alone does not significantly suppress appetite or promote weight loss, it acts synergistically when combined with GLP-1. Endocrinologists often compare the relationship to a battery and a flashlight: GIP provides an extra metabolic boost that supercharges the baseline effects of GLP-1.[4]

GIP signaling influences how fat cells store and release energy, improving the body's ability to metabolize lipids efficiently. It also activates distinct but overlapping satiety centers in the brain, creating a complementary fullness signal that often results in slightly higher average weight loss than targeting the GLP-1 pathway alone.[4][6]

Delivering these complex peptide hormones orally has historically been considered impossible. The human stomach is a hostile environment explicitly designed to break down proteins; stomach acid and digestive enzymes typically destroy peptide-based drugs long before they can be absorbed into the bloodstream.[5]

Novo Nordisk solved this biological hurdle by co-formulating semaglutide with a specialized absorption enhancer. This compound temporarily neutralizes stomach acid in a localized area around the dissolving pill, allowing the semaglutide molecule to cross the gastric lining intact.[5]

Even with this chemical armor, oral bioavailability remains incredibly low. Only about 1% of an oral semaglutide dose is actually absorbed into the systemic circulation, compared to nearly 100% absorption from a standard subcutaneous injection.[5]

To compensate for this massive drop in efficiency, the oral version requires vastly higher doses. While the maximum weekly injection of Wegovy is 2.4 milligrams, the newly approved daily pill reaches doses of up to 25 milligrams per day.[5][7]

Despite the biological hurdles, clinical data proves the pill works. In the OASIS 4 phase 3 clinical trial, patients taking the 25mg daily oral dose achieved an average weight loss of 16.6% over 64 weeks when combined with diet and exercise. This efficacy is statistically comparable to the results seen with the injectable version.[7][8]

However, the pill comes with strict administration rules to ensure that the crucial 1% absorption actually happens. Patients must take the tablet on an empty stomach immediately upon waking, with no more than half a glass of water, and wait at least 30 minutes before eating, drinking, or taking other medications.[5]

Side effects for the oral formulation closely mirror those of the injection, primarily centering on gastrointestinal distress. Nausea, diarrhea, vomiting, and constipation are common, particularly as patients titrate up through the 1.5mg, 4mg, and 9mg starting doses over several months to let their bodies adjust.[7]

The UK approval gives Novo Nordisk a crucial head start in the oral weight-loss market. Eli Lilly is currently developing its own once-daily pill, orforglipron, but that therapy remains in clinical trials and is not yet available to the public.[3]

As prescriptions for oral semaglutide surpass three million globally following its earlier launch in the US and UAE, the UK rollout represents a major test of manufacturing capacity. If supply chains hold, the needle-free option could significantly expand the population willing to initiate long-term obesity treatment, fundamentally shifting how metabolic health is managed.[2][8]